Customer Demand Communication and Project Design
We begin with in-depth discussions to understand your specific research objectives, tailoring a precise experimental design.
We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.
Creative Biolabs provides comprehensive, customized oligonucleotide-based anti-monkeypox drug discovery solutions. From initial design to rigorous validation, our services are meticulously crafted to accelerate your research and development process, bringing effective antiviral therapies closer to patients with unparalleled efficiency and precision.
Monkeypox, caused by the Monkeypox virus (MPXV), is a zoonotic orthopoxvirus that has recently garnered global attention due to its widespread human-to-human transmission. While typically milder than smallpox, the 2022 outbreak highlighted the critical need for novel and rapidly deployable antiviral strategies.
Oligonucleotides, short synthetic nucleic acid sequences, represent a cutting-edge therapeutic modality. These molecules are engineered to specifically bind to target nucleic acids or proteins, thereby modulating gene expression or inhibiting protein function. This highly targeted approach offers a powerful alternative to conventional antiviral agents, promising high specificity and reduced off-target effects in the fight against MPXV.
Figure.1 Mechanism of action of antisense RNA. (Reza, 2021)
Creative Biolabs offers comprehensive oligonucleotide-based anti-Monkeypox drug discovery solutions, spanning from sophisticated design to robust in vitro and in vivo validation. Our integrated services are designed to propel your pipeline forward efficiently and effectively.
This strategy harnesses the power of short RNA fragments specifically designed to influence target DNA or RNA molecules by triggering the degradation of complementary viral mRNA. This effectively silences essential viral gene expression and prevents replication, offering a potent antiviral mechanism.
ASO Design and Optimization:
Utilizing bioinformatics tools to identify optimal viral mRNA targets and design ASO sequences with high specificity and binding affinity.
Cell Culture-Based Antiviral Assays:
Evaluating the inhibitory effect of ASOs on MPXV replication in various cell lines using techniques such as plaque assays, RT-qPCR for viral load reduction, and Western blotting for viral protein expression.
Mechanism of Action Studies:
Investigating the precise molecular mechanisms by which ASOs exert their antiviral effects, including RNase H-dependent cleavage, steric hindrance, and splicing modulation.
Toxicity Profiling:
Assessing the cytotoxicity of ASO candidates in relevant cell lines to ensure minimal off-target effects.
Animal Model Development:
Establishing and characterizing appropriate animal models for Monkeypox infection (e.g., non-human primates, small animal models) to evaluate ASO efficacy.
PK/PD Studies:
Determining the absorption, distribution, metabolism, and excretion (ADME) profiles of ASOs, as well as their concentration-dependent antiviral effects in target tissues.
Efficacy Evaluation:
Assessing the therapeutic potential of ASOs in infected animals by monitoring viral load reduction in various organs, clinical symptom improvement, and survival rates.
Toxicity and Safety Assessment:
Comprehensive evaluation of potential adverse effects and overall safety profile of ASO candidates in animal models.
AODNs are synthetic single-stranded DNA oligonucleotides meticulously engineered to block ribosomal translation of critical viral proteins. They can also stimulate the degradation of specific viral RNA sequences, thereby precisely disrupting the MPXV's life cycle at a fundamental molecular level.
ASODN Design and Synthesis:
Rational design of ASODN sequences targeting essential Monkeypox viral genes or regulatory regions, followed by high-quality synthesis.
Cell-Based Antiviral Screening:
High-throughput screening of ASODN libraries against MPXV in cellular infection models, measuring viral replication inhibition through reporter assays or viral quantification.
Specificity and Off-Target Analysis:
Verifying the specific binding of ASODNs to their intended viral targets and assessing potential off-target interactions with host cellular components.
Stability and Nuclease Resistance Assays:
Evaluating the in vitro stability of ASODNs in biological fluids and their resistance to nuclease degradation.
Pre-Clinical Efficacy Studies:
Testing the antiviral efficacy of lead ASODN candidates in established Monkeypox animal models, assessing parameters such as viral burden reduction, lesion resolution, and disease progression.
Biodistribution Studies:
Tracking the distribution of ASODNs within the animal body to identify target organs and ensure efficient delivery to sites of viral replication.
Immunogenicity Assessment:
Evaluating potential immune responses elicited by ASODN administration, including cytokine profiles and antibody production.
Safety Pharmacology:
Conducting studies to assess the effects of ASODNs on vital physiological functions in animals to identify any potential adverse effects.
We begin with in-depth discussions to understand your specific research objectives, tailoring a precise experimental design.
A clear contract is established, and your project launches, ensuring transparency and a smooth transition into the operational phase.
Our skilled scientific team meticulously carries out all experimental stages, adhering to high scientific standards and utilizing state-of-the-art methodologies.
Comprehensive data analysis is conducted, followed by detailed and professional reports that present findings, interpretations, and implications.
Final results are delivered promptly, with ongoing consultation and support for data interpretation and future research planning.
Click the button to contact us for service details and a custom quote.
Oligonucleotides exert their anti-Monkeypox effects by precisely interfering with the virus's replication cycle at a molecular level. ASOs and small interfering RNAs (siRNAs) can specifically target essential MPXV messenger RNA sequences, preventing the translation of crucial viral proteins like DNA polymerase or structural components, thereby halting viral replication. Alternatively, aptamers can bind to viral surface proteins, blocking the virus's ability to enter host cells. Furthermore, oligonucleotides can modulate host cellular pathways hijacked by the virus or enhance the host's innate antiviral defenses, providing a multi-pronged attack against MPXV infection.
Figure.2 Mechanism of action of antisense oligonucleotides. (Reza, 2021)
Advanced Platforms
We utilize cutting-edge bioinformatics tools and high-throughput synthesis and screening platforms, ensuring optimal outcomes at every stage of your drug discovery journey.
Fully Customizable Design
Our experimental designs are entirely flexible, allowing for tailored approaches that extend beyond standard procedures to meet your unique research specifications.
Competitive Pricing
We offer highly competitive pricing without compromising on the superior quality and scientific rigor of our services.
Reliable Reporting
You will receive comprehensive and reliable lab reports with transparent data and timely updates, keeping you informed throughout the project.
Dedicated Scientific Support
Our team of expert scientists provides continuous guidance and consultation, offering invaluable insights and problem-solving assistance at every step.
Our design process integrates advanced bioinformatics algorithms and extensive genomic analysis of the MPXV. This rigorous approach allows us to identify highly unique and conserved viral sequences, minimizing potential off-target effects and maximizing the specificity of our oligonucleotide candidates.
All in vitro studies involving live MPXV are conducted within our state-of-the-art Biosafety Level 3 (BSL-3) containment facilities. This ensures the utmost safety for our personnel and the environment while maintaining the integrity of your research.
Absolutely. We provide comprehensive support for in vivo efficacy studies using relevant animal models. Our services include experimental design, administration of oligonucleotide candidates, monitoring of viral load, and assessment of disease progression to evaluate therapeutic potential.
Effective delivery is paramount for oligonucleotide therapeutics. Creative Biolabs offers expertise in various delivery strategies, including the use of lipid nanoparticles (LNPs), chemical modifications for enhanced stability, and conjugation with targeting ligands to optimize cellular uptake and bioavailability.
Yes, custom oligonucleotide synthesis is a core service we provide. We can synthesize a wide range of modified oligonucleotides to meet your specific research requirements, ensuring high purity and quality for your experimental applications.
Creative Biolabs is a leading service provider that focuses on anti-monkeypox drug development. We can assist you in designing the best research outline customized to meet the requirements of clients' programs. If you are interested in our services and products, please do not hesitate to contact us for more details.
Reference
We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.